Xeris Pharmaceuticals has teamed up with the American Diabetes Association (ADA) to raise awareness of the importance of ...
adding that it had mutually agreed with Xeris BioPharma to return the rights to Ogluo - a ready-to-use glucagon auto-injector for severe hypoglycemia. The AIM-traded firm said the decision ...
The move comes alongside a mutual decision with Xeris BioPharma Holdings, Inc. (Nasdaq: XERS) to return the commercial rights to Ogluo®, a glucagon auto-injector pen for severe hypoglycemia. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback